HTR1A and prostate cancer: It appeared that almost all of the examined compounds (besides 5-HT1A receptor agonist 8-OH-DPAT, SSRI fluvoxamine against SH-SY5Y and AB9 against both tumor lines) exhibited moderate to high cytotoxic activity at the micromolar level against neuroblastoma and prostate cancer cells (Table 2).